28 results
8-K
EX-99.5
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
occur, the Company’s ability to achieve its development and commercialization goals would be adversely affected.
Accordingly, due to these uncertainties
8-K
EX-99.4
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
, the Company’s ability to achieve its development and commercialization goals would be adversely affected.
Accordingly, due to these uncertainties
8-K
EX-99.2
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
begins an in-depth review of the BLA. Under the goals and policies agreed to by the FDA under the Prescription Drug User Fee Act (“PDUFA”), the FDA has
8-K
EX-10.1
ELYM
Eliem Therapeutics Inc
12 Jun 24
Departure of Directors or Certain Officers
4:41pm
, and based, in part, on your performance and the performance of the Company against performance goals mutually agreed upon between the Board
DEFM14A
ELYM
Eliem Therapeutics Inc
4 Jun 24
Proxy related to merger
8:00am
is accepted for filing, the FDA begins an in-depth review of the BLA. Under the goals and policies agreed to by the FDA under the Prescription Drug User Fee Act … development and commercialization goals would be adversely affected.
Accordingly, due to these uncertainties, there is substantial doubt about
PREM14A
t37ogzab adu0
17 May 24
Preliminary proxy related to merger
4:36pm
8-K
w4j0uc h4t
20 Dec 22
Departure of Directors or Certain Officers
4:02pm
DEF 14A
qjztcw
8 Apr 22
Definitive proxy
4:20pm
8-K
EX-99.1
9ixh wuerqi8b5x0
29 Mar 22
Regulation FD Disclosure
7:43am
10-K
yly na1eeku2
7 Mar 22
Annual report
4:03pm
8-K
6pcrc 7o3hqo
31 Jan 22
Departure of Directors or Certain Officers
5:16pm
8-K
EX-99.2
027m7wi
8 Nov 21
Eliem Therapeutics Reports Third Quarter Financial and Business Highlights
4:06pm
424B4
1v77839un
11 Aug 21
Prospectus supplement with pricing info
5:05pm
S-1/A
l7xvz772
2 Aug 21
IPO registration (amended)
6:08am
S-1/A
EX-10.9
3y938tmpu
2 Aug 21
IPO registration (amended)
6:08am